Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Moodys
Merck
Medtronic
Dow

Last Updated: January 28, 2022

DrugPatentWatch Database Preview

Claims for Patent: 10,188,745

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,188,745
Title:Binding protein drug conjugates comprising anthracycline derivatives
Abstract: The present invention relates to an anthracycline (PNU) derivative conjugate comprising a derivative of the anthracycline PNU-159682 having the formula (i) or formula (ii) which further comprises a linker structure X-L1-L2-L3-Y.
Inventor(s): Grawunder; Ulf (Basel, CH), Beerli; Roger Renzo (Basel, CH)
Assignee: NBE-THERAPEUTICS AG (Basel, CH)
Application Number:15/539,518
Patent Claims:1. A binding protein-drug conjugate (BPDC) comprising an anthracycline (PNU) derivative, the BPDC having the following formula: ##STR00006## wherein a) each of L.sub.1-L.sub.3 represents a linker, wherein L.sub.1 is optional and both L.sub.2 and L.sub.3 are mandatory, b) L.sub.1, when present, represents an alkylene-amino linker or an alkylene-diamino linker, c) L.sub.2 represents an oligo-glycine peptide, d) L.sub.3 represents a peptide motif that results from specific cleavage of a sortase enzyme recognition motif, e) X and Y each represent one or more optional linkers, f) BP is a binding protein, and g) n is an integer .gtoreq.1 and .ltoreq.10.

2. The binding protein-drug conjugate according to claim 1, wherein the oligo: glycine peptide is conjugated to the anthracycline derivative by means of an ethylenediamino linker (EDA), designated as L.sub.1, which ethylenediamino linker is conjugated to the anthracycline derivative by means of a first amide bond, while it is conjugated to the carboxy terminus of the oligo-glycine peptide by means of a second amide bond.

3. The binding protein-drug conjugate according to claim 1, wherein said sortase enzyme recognition motif comprises a pentapeptide.

4. The binding protein-drug conjugate according to claim 1, wherein said sortase enzyme recognition motif comprises at least one amino acid sequence selected from the group consisting of (N-terminal to C-terminal) LPXTG (SEQ ID NO: 5), LPXSG (SEQ ID NO: 6), and LAXTG (SEQ ID NO: 7), wherein X in each of SEQ ID NOs: 5-7 represents any amino acid.

5. The binding protein-drug conjugate according to claim 1, wherein the anthracycline (PNU) derivative is conjugated, by means of the two or more linkers, to the carboxy terminus of the binding protein, or to the carboxy terminus of at least one domain or subunit thereof.

6. The binding protein-drug conjugate according to claim 1, wherein the binding protein is at least one selected from the group consisting of an antibody, modified antibody format, antibody derivative or fragment, antibody-based binding protein, oligopeptide binder and an antibody mimetic.

7. The binding protein-drug conjugate according to claim 1, wherein the binding protein binds at least one entity selected from the group consisting of a receptor, an antigen, a growth factor, a cytokine, and a hormone.

8. The binding protein-drug conjugate according to claim 1, wherein the binding protein comprises at least two subunits.

9. The binding protein-drug conjugate according to claim 8, wherein at least one subunit comprises the anthracycline derivative.

10. The binding protein-drug conjugate according to claim 1, wherein the binding protein binds HER-2.

11. The binding protein-drug conjugate according to claim 10, wherein the binding protein is an antibody that binds HER-2.

12. The binding protein-drug conjugate according to claim 11, wherein the antibody comprises the CDR regions 1-6 of trastuzumab.

13. The binding protein-drug conjugate according to claim 11, wherein the antibody comprises the heavy chain variable domain and the light chain variable domain of trastuzumab.

14. The binding protein-drug conjugate according to claim 11, wherein the antibody has an amino acid sequence identity of 90% or higher with the heavy chain variable domain or the light chain variable domain of trastuzumab.

15. The binding protein-drug conjugate according to claim 11, wherein the antibody competes with trastuzumab for binding to HER2.

16. The binding protein-drug conjugate according to claim 1, wherein the binding protein binds CD30.

17. The binding protein-drug conjugate according to claim 16, wherein the binding protein is an antibody that binds CD30.

18. The binding protein-drug conjugate according to claim 17, wherein the antibody comprises the CDR regions 1-6 of brentuximab.

19. The binding protein-drug conjugate according to claim 17, wherein the antibody comprises the heavy chain variable domain and the light chain variable domain of brentuximab.

20. The binding protein-drug conjugate according to claim 17, wherein the antibody has an amino acid sequence identity of 90% or higher with the heavy chain variable domain or the light chain variable domain of brentuximab.

21. The binding protein-drug conjugate according to claim 17, wherein the antibody competes with brentuximab for binding to CD30.

22. A pharmaceutical composition comprising the binding protein drug conjugate according to claim 1, and at least one other pharmaceutically acceptable ingredient.

23. The binding protein drug conjugate according to claim 1, wherein the binding protein is an antibody.

24. A binding protein-drug conjugate (BPDC) comprising an anthracycline (PNU) derivative, the BPDC having the following formula: ##STR00007## wherein a) X is absent, b) L.sub.1 represents ethylenediamine (EDA), c) L.sub.2 represents an oligo-glycine peptide (Gly).sub.p, wherein p is an integer .gtoreq.1 and .ltoreq.21, d) L.sub.3 consists of amino acid residues 1-4 of a processed sortase enzyme recognition motif (N-terminal to C-terminal) Leu-Pro-Xaa-Thr-Gly (LPXTG) (SEQ ID NO: 5, wherein Xaa is any amino acid), e) Y, when present, is (N-terminal to C-terminal) Gly-Gly-Gly-Gly-Ser (G.sub.4S) (SEQ ID NO: 8), f) BP is an IgG antibody, and g) n is an integer .gtoreq.1 and .ltoreq.10.

25. The binding protein conjugate according to claim 24, wherein the N-terminal Gly of Y is linked to the last C-terminal Cys amino acid of at least one light chain of the antibody.

26. The binding protein-drug conjugate according to claim 24, wherein the antibody comprises the heavy chain variable domain and the light chain variable domain of trastuzumab.

27. The binding protein-drug conjugate according to claim 24, wherein the antibody has an amino acid sequence identity of 90% or higher with the heavy chain variable domain or the light chain variable domain of trastuzumab.

28. The binding protein-drug conjugate according to claim 24, wherein the antibody competes with trastuzumab for binding to HER2.

Details for Patent 10,188,745

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Sign up for a Free Trial 2039-02-26
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Sign up for a Free Trial 2039-02-26
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 2019-02-28 ⤷  Sign up for a Free Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
AstraZeneca
Johnson and Johnson
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.